NASDAQ:RSLS ReShape Lifesciences (RSLS) Stock Price, News & Analysis $4.56 -0.02 (-0.44%) As of 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About ReShape Lifesciences Stock (NASDAQ:RSLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ReShape Lifesciences alerts:Sign Up Key Stats Today's Range$4.34▼$4.8050-Day Range$4.58▼$39.7552-Week Range$4.41▼$725.00Volume18,242 shsAverage Volume186,465 shsMarket Capitalization$3.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.Read More… ReShape Lifesciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreRSLS MarketRank™: ReShape Lifesciences scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ReShape Lifesciences.Read more about ReShape Lifesciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ReShape Lifesciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ReShape Lifesciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReShape Lifesciences has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ReShape Lifesciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.29% of the float of ReShape Lifesciences has been sold short.Short Interest Ratio / Days to CoverReShape Lifesciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ReShape Lifesciences has recently decreased by 39.64%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReShape Lifesciences does not currently pay a dividend.Dividend GrowthReShape Lifesciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.29% of the float of ReShape Lifesciences has been sold short.Short Interest Ratio / Days to CoverReShape Lifesciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ReShape Lifesciences has recently decreased by 39.64%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment0.97 News SentimentReShape Lifesciences has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ReShape Lifesciences this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for RSLS on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added ReShape Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ReShape Lifesciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of ReShape Lifesciences is held by insiders.Percentage Held by InstitutionsOnly 22.06% of the stock of ReShape Lifesciences is held by institutions.Read more about ReShape Lifesciences' insider trading history. Receive RSLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RSLS Stock News HeadlinesReShape Lifesciences (NASDAQ:RSLS) Raised to "Hold" at Wall Street ZenMay 26 at 1:33 AM | americanbankingnews.comReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate UpdateMay 21, 2025 | globenewswire.comHow Trade Wars Are Creating Fresh Opportunities for InvestorsTariffs and trade tensions are back in the headlines, and while many are focused on the risks, smart investors know there’s also opportunity. New supply chain shifts, pricing power adjustments, and sector revaluations are already underway—creating openings for those who act early. That’s why we’ve just released our latest research: 📈 “From Tariffs to Returns: How to Capitalize on Trade Disputes in Your Portfolio”May 29, 2025 | Darwin (Ad)ReShape Lifesciences Inc: ReShape Lifesciences Announces 1-for-25 Reverse Stock SplitMay 7, 2025 | finanznachrichten.deReShape Lifesciences Announces 1-for-25 Reverse Stock SplitMay 7, 2025 | globenewswire.comStocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock ChatterMay 5, 2025 | msn.comPRISM Mid-Day Movers: Weight Loss Index Gains on Positive Data, Biotech Slumps on Disappointing ResultsMay 3, 2025 | theglobeandmail.comReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation SymposiumMay 2, 2025 | globenewswire.comSee More Headlines RSLS Stock Analysis - Frequently Asked Questions How have RSLS shares performed this year? ReShape Lifesciences' stock was trading at $111.50 at the start of the year. Since then, RSLS shares have decreased by 95.9% and is now trading at $4.56. View the best growth stocks for 2025 here. How were ReShape Lifesciences' earnings last quarter? ReShape Lifesciences Inc. (NASDAQ:RSLS) issued its quarterly earnings results on Tuesday, May, 20th. The medical device company reported $18.98 EPS for the quarter. The medical device company earned $1.11 million during the quarter. ReShape Lifesciences had a negative net margin of 86.36% and a negative trailing twelve-month return on equity of 179.83%. When did ReShape Lifesciences' stock split? Shares of ReShape Lifesciences reverse split before market open on Monday, September 23rd 2024. The 1-58 reverse split was announced on Thursday, September 19th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of ReShape Lifesciences? Shares of RSLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ReShape Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that ReShape Lifesciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Digital Turbine (APPS), Nano Dimension (NNDM), CrowdStrike (CRWD) and Company Calendar Last Earnings5/20/2025Today5/29/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:RSLS CIK1371217 Webwww.reshapelifesciences.com Phone(949) 429-6680FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($193.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.39 million Net Margins-86.36% Pretax Margin-85.56% Return on Equity-179.83% Return on Assets-91.48% Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio0.60 Sales & Book Value Annual Sales$7.18 million Price / Sales0.46 Cash FlowN/A Price / Cash FlowN/A Book Value$29.49 per share Price / Book0.15Miscellaneous Outstanding Shares738,000Free Float729,000Market Cap$3.32 million OptionableNot Optionable Beta1.48 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:RSLS) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReShape Lifesciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ReShape Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.